27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Lawsuit
The U.S. District Court in Delaware's permanent injunction preventing Regeneron and Sanofi from infringing two patents held by Amgen for Repatha comes on heels of a jury verdict in March 2016 in favor of Amgen in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9.
However, the district court has not made its ruling take effect immediately, giving the defendants a 30-day opportunity to seek expedited review of this decision.
Repatha, a human monoclonal antibody, which increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels, by inhibiting the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to LDLR (low-density lipoprotein receptor).
Appeal
Meanwhile, Sanofi and Regeneron announced they will appeal the injunction granted for marketing, selling or manufacturing of Praluent in the United States during the term of two Amgen patents.
Sanofi shares were down 3.18 percent, and Regeneron was slumping 5.74 percent in pre-market trading. Amgen was up 3.77 percent.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!